Medpace (NASDAQ:MEDP – Get Free Report) had its price objective raised by equities research analysts at Robert W. Baird from $547.00 to $624.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s target price points to a potential upside of 3.00% from the company’s previous close.
MEDP has been the subject of a number of other reports. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and lifted their price target for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday. Mizuho increased their target price on Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $508.42.
Get Our Latest Stock Analysis on Medpace
Medpace Price Performance
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 109.14%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the company posted $3.10 EPS. The company’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace will post 17.04 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 20.50% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the 4th quarter worth approximately $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace during the fourth quarter worth $30,000. Allied Private Wealth LLC purchased a new position in shares of Medpace in the second quarter valued at $31,000. Basecamp Wealth Advisors LLC boosted its stake in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the period. Finally, Quarry LP acquired a new stake in Medpace during the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 77.98% of the company’s stock.
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off?
- Microsoft Earnings Are Coming—But Azure and CapEx Will Decide the Reaction
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
